1
|
Silva GB, Velasco-Tamariz V, Mitsunaga K, Ortiz-Romero PL. Hair repigmentation in Sézary syndrome. J Eur Acad Dermatol Venereol 2024. [PMID: 38400643 DOI: 10.1111/jdv.19895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Accepted: 02/09/2024] [Indexed: 02/25/2024]
Affiliation(s)
- G B Silva
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Medical School, Universidad Complutense, Madrid, Spain
| | - V Velasco-Tamariz
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Medical School, Universidad Complutense, Madrid, Spain
| | - K Mitsunaga
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Medical School, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Medical School, Universidad Complutense, Madrid, Spain
| |
Collapse
|
2
|
Rubio-Muniz CA, Sánchez-Velázquez A, Arroyo-Andrés J, Agud-de Dios M, Tarín-Vicente EJ, Falkenhain-López D, Ortiz-Romero PL. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases. J Eur Acad Dermatol Venereol 2024; 38:e102-e105. [PMID: 37611255 DOI: 10.1111/jdv.19457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 08/16/2023] [Indexed: 08/25/2023]
Affiliation(s)
- C A Rubio-Muniz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Sánchez-Velázquez
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J Arroyo-Andrés
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Agud-de Dios
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E J Tarín-Vicente
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - D Falkenhain-López
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
- Institute i+12 CIBERONC, Medical School, University Complutense, Madrid, Spain
| |
Collapse
|
3
|
Guenova E, Ortiz-Romero PL, Poligone B, Querfeld C. Mechanism of action of chlormethine gel in mycosis fungoides. J Eur Acad Dermatol Venereol 2023; 37:1739-1748. [PMID: 37262305 DOI: 10.1111/jdv.19237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Accepted: 05/11/2023] [Indexed: 06/03/2023]
Abstract
Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, is characterized by proliferation of malignant skin-tropic T cells. Progression from early-stage disease (skin patches and/or plaques) to more advanced stages (cutaneous tumours, erythroderma or extracutaneous involvement) occurs slowly and can be discontinuous. Prognosis is poor for the ~25% of patients who progress to advanced disease. Patients at any stage of MF may experience reduced health-related quality of life (QoL) via a spectrum of physically and psychologically debilitating symptoms that can impact many aspects of daily life. Allogeneic stem-cell transplantation is a curative treatment option for some patients with advanced disease, but otherwise there is currently no cure for MF; patients are often refractory to several treatments and require lifelong management. The goals of therapy are symptom control, prevention of disease progression, avoidance of treatment-related toxicity and maintenance/improvement of QoL. Although treatment regimens exist it can be difficult to know how to prioritize them, hence therapies are tailored according to patient needs and drug availabilities, following clinical recommendations. International consensus guidelines recommend skin-directed therapies (SDTs) as first-line treatment for early-stage disease, and SDTs combined with systemic therapy for advanced stages. Chlormethine (CL), also known as mechlorethamine, chlorethazine, mustine, HN2, caryolysine and embichin, is a synthetic deoxyribonucleic acid-alkylating agent that was used as a chemical weapon (mustard gas) during the First World War. Subsequent investigation revealed that survivors of mustard gas exposure had lymphocytopenia, and that CL could inhibit rapidly proliferating malignant T cells. CL has since been developed as a topical treatment for MF and prescribed as such for over 70 years. This review aims to summarize the current knowledge regarding the mechanism of action of CL in the cutaneous micro-environment, in the specific context of MF treatment.
Collapse
Affiliation(s)
- E Guenova
- University Hospital Lausanne (CHUV), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - P L Ortiz-Romero
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital 12 de Octubre, University Complutense, Madrid, Spain
| | - B Poligone
- Rochester Skin Lymphoma Medical Group, Fairport, New York, USA
| | - C Querfeld
- Division of Dermatology, Department of Pathology, City of Hope National Medical Center, Beckman Research Institute, Duarte, California, USA
| |
Collapse
|
4
|
Onteniente-Gomis MM, Ortiz-Romero PL, Tous Romero F, Salamanca Castro AB, Ortiz de Frutos FJ. [[Translated article]]Spanish Version of the RECAP Questionnaire to Assess Control of Atopic Eczema: Translation, Cultural Adaptation, Validation, and Correlations with Other Patient-Reported Outcome Measures. Actas Dermosifiliogr 2023:S0001-7310(23)00347-2. [PMID: 37172895 DOI: 10.1016/j.ad.2023.05.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/26/2023] [Indexed: 05/15/2023] Open
Abstract
BACKGROUND The 7-item RECAP (Recap of Atopic Eczema) questionnaire is used to assess the control of different degrees of eczema severity in patients of all ages. Long-term control of eczema is one of the 4 core outcome domains to be assessed in clinical trials of eczema therapies. After the RECAP was developed in the United Kingdom, it was translated into Chinese, German, Dutch, and French. OBJECTIVES To produce a validated Spanish version of the RECAP questionnaire and, secondarily, to test its content validity in a group of Spanish patients with atopic eczema. MATERIAL AND METHODS In a 7-step process we produced 2 forward translations and 1 back translation of the RECAP questionnaire. Experts then held 2 meetings to reach consensus and draft Spanish version of the questionnaire. Fifteen adult patients with atopic eczema were interviewed to evaluate the comprehensibility, comprehensiveness, and relevance of the drafted items. These patients also completed the Atopic Dermatitis Control Tool (ADCT), the Dermatology Life Quality Index (DLQI), and the Patient-Oriented Eczema Measure (POEM). Stata software (version 16) was then used to explore the correlations between the patients' scores on these tools and the RECAP. RESULTS The patients found the Spanish version of the RECAP to be comprehensible and easy to answer. We observed a strong correlation between results on the Spanish RECAP and the ADCT, and highly significant correlations between the RECAP and the DLQI and POEM tools. CONCLUSIONS The culturally adapted Spanish version of the RECAP is linguistically equivalent to the original version of the questionnaire. RECAP scores correlate highly with other patient-reported outcome measures.
Collapse
Affiliation(s)
- M M Onteniente-Gomis
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España; Universidad complutense, Madrid, España
| | - F Tous Romero
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - A B Salamanca Castro
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - F J Ortiz de Frutos
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España.
| |
Collapse
|
5
|
Onteniente-Gomis MM, Ortiz-Romero PL, Tous Romero F, Salamanca Castro AB, Ortiz de Frutos FJ. Spanish Version of the Recap Questionnaire to Assess Control of Atopic Eczema: Translation, Cultural Adaptation, Validation, and Correlations With Other Patient-Reported Outcome Measures. Actas Dermosifiliogr 2023:S0001-7310(23)00174-6. [PMID: 36935038 DOI: 10.1016/j.ad.2023.02.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/26/2023] [Indexed: 03/19/2023] Open
Abstract
BACKGROUND The 7-item RECAP (Recap of Atopic Eczema) questionnaire is used to assess the control of different degrees of eczema severity in patients of all ages. Long-term control of eczema is one of the 4 core outcome domains to be assessed in clinical trials of eczema therapies. After the RECAP was developed in the United Kingdom, it was translated into Chinese, German, Dutch, and French. OBJECTIVES To produce a validated Spanish version of the RECAP questionnaire and, secondarily, to test its content validity in a group of Spanish patients with atopic eczema. MATERIAL AND METHODS In a 7-step process we produced 2 forward translations and 1 back translation of the RECAP questionnaire. Experts then held 2 meetings to reach consensus and draft Spanish version of the questionnaire. Fifteen adult patients with atopic eczema were interviewed to evaluate the comprehensibility, comprehensiveness, and relevance of the drafted items. These patients also completed the Atopic Dermatitis Control Tool (ADCT), the Dermatology Life Quality Index (DLQI), and the Patient-Oriented Eczema Measure (POEM). Stata software (version 16) was then used to explore the correlations between the patients' scores on these tools and the RECAP. RESULTS The patients found the Spanish version of the RECAP to be comprehensible and easy to answer. We observed a strong correlation between results on the Spanish RECAP and the ADCT, and highly significant correlations between the RECAP and the DLQI and POEM tools. CONCLUSIONS The culturally adapted Spanish version of the RECAP is linguistically equivalent to the original version of the questionnaire. RECAP scores correlate highly with other patient-reported outcome measures.
Collapse
Affiliation(s)
- M M Onteniente-Gomis
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España; Universidad complutense, Madrid, España
| | - F Tous Romero
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - A B Salamanca Castro
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España
| | - F J Ortiz de Frutos
- Departamento de Dermatología, Hospital Universitario 12 de octubre. Instituto i+12, Madrid, España.
| |
Collapse
|
6
|
Falkenhain-López D, Muniesa C, Estrach MT, Morillo-Andújar M, Peñate Y, Acebo E, Pujol RM, García-Muret MP, Machan S, Medina S, Botella-Estrada R, Fernández de Misa R, Blanes M, Flórez A, Pérez-Paredes G, Izu R, Yanguas I, Silva-Díaz E, Pérez-Ferriols A, Prieto-Torres L, Zayas A, Parera-Amer ME, Pérez A, Aspe L, Román C, Sánchez-Caminero MP, Bassas-Vila J, Domínguez-Auñón JD, Calzado L, Navedo M, Ortiz-Prieto A, Servitje O, Polo-Rodríguez I, Torres I, Hernández-Hernández MN, Mitxelena-Eceiza J, García-Vázquez A, García-Doval I, Ortiz-Romero PL. [Translated article] Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermosifiliogr 2023; 114:T291-T298. [PMID: 36848951 DOI: 10.1016/j.ad.2022.11.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Accepted: 11/12/2022] [Indexed: 02/27/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of the Spanish Academy of Dermatology and Venereology (AEDV) were published in February 2018. This report covers RELCP data for the first 5 years. PATIENTS AND METHODS RELCP data were collected prospectively and included diagnosis, treatments, tests, and the current status of patients. We compiled descriptive statistics of the data registered during the first 5 years. RESULTS Information on 2020 patients treated at 33 Spanish hospitals had been included in the RELCP by December 2021. Fifty-nine percent of the patients were men; the mean age was 62.2 years. The lymphomas were grouped into 4 large diagnostic categories: mycosis fungoides/Sézary syndrome, 1112 patients (55%); primary B-cell cutaneous lymphoma, 547 patients (27.1%); primary CD30+ lymphoproliferative disorders, 222 patients (11%), and other T-cell lymphomas, 116 patients (5.8%). Nearly 75% of the tumors were registered in stage I. After treatment, 43.5% achieved complete remission and 27% were stable at the time of writing. Treatments prescribed were topical corticosteroids (1369 [67.8%]), phototherapy (890 patients [44.1%]), surgery (412 patients [20.4%]), and radiotherapy (384 patients [19%]). CONCLUSION The characteristics of cutaneous lymphomas in Spain are similar to those reported for other series. The large size of the RELCP registry at 5 years has allowed us to give more precise descriptive statistics than in the first year. This registry facilitates the clinical research of the AEDV's lymphoma interest group, which has already published articles based on the RELCP data.
Collapse
Affiliation(s)
- D Falkenhain-López
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain.
| | - C Muniesa
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M T Estrach
- Departamento de Dermatología, Hospital Clínico, IDIBAPS, Universitario de Barcelona, Barcelona, Spain
| | - M Morillo-Andújar
- Departamento de Dermatología, Hospital Virgen del Rocío, Sevilla, Spain
| | - Y Peñate
- Departamento de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Spain
| | - E Acebo
- Departamento de Dermatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
| | - R M Pujol
- Departamento de Dermatología, Hospital del Mar, Barcelona, Spain
| | - M P García-Muret
- Departamento de Dermatología, Hospital Santa Creu i Sant Pau, UAB Barcelona, Barcelona, Spain
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - S Medina
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - R Botella-Estrada
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, Spain
| | - R Fernández de Misa
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
| | - M Blanes
- Departamento de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain
| | - A Flórez
- Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - G Pérez-Paredes
- Departamento de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander Cantabria, Spain
| | - R Izu
- Departamento de Dermatología, Hospital Universitario de Basurto, Bilbao, Bizkaia, Spain
| | - I Yanguas
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, Spain
| | - E Silva-Díaz
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - A Pérez-Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain
| | - L Prieto-Torres
- Departamento de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - A Zayas
- Departamento de Dermatología, Hospital Universitario Dr. Peset, Valencia, Spain
| | - M E Parera-Amer
- Departamento de Dermatología, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, Spain
| | - A Pérez
- Departamento de Dermatología, Hospital Universitario Nuestra Señora De Valme, Sevilla, Spain
| | - L Aspe
- Departamento de Dermatología, Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, Spain
| | - C Román
- Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, Spain
| | - M P Sánchez-Caminero
- Departamento de Dermatología, Hospital General de Ciudad Real, Ciudad Real, Spain
| | - J Bassas-Vila
- Departamento de Dermatología, Hospital Germans Trias i Pujol, Barcelona, Spain
| | - J D Domínguez-Auñón
- Departamento de Dermatología, Hospital Universitario del Henares, Coslada, Madrid, Spain
| | - L Calzado
- Departamento de Dermatología, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain
| | - M Navedo
- Departamento de Dermatología, Complejo Asistencial Universitario de León, León, Spain
| | - A Ortiz-Prieto
- Departamento de Dermatología, Hospital Puerta del Mar, Cádiz, Spain
| | - O Servitje
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain
| | - I Polo-Rodríguez
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - I Torres
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, Spain
| | - M N Hernández-Hernández
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain
| | - J Mitxelena-Eceiza
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, Spain
| | - A García-Vázquez
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain; Departamento de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
7
|
Falkenhain-López D, Muniesa C, Estrach MT, Morillo-Andújar M, Peñate Y, Acebo E, Pujol RM, García-Muret MP, Machan S, Medina S, Botella-Estrada R, Fernández de Misa R, Blanes M, Flórez A, Pérez-Paredes G, Izu R, Yanguas I, Silva-Díaz E, Pérez-Ferriols A, Prieto-Torres L, Zayas A, Parera-Amer ME, Pérez A, Aspe L, Román C, Sánchez-Caminero MP, Bassas-Vila J, Domínguez-Auñón JD, Calzado L, Navedo M, Ortiz-Prieto A, Servitje O, Polo-Rodríguez I, Torres I, Hernández-Hernández MN, Mitxelena-Eceiza J, García-Vázquez A, García-Doval I, Ortiz-Romero PL. Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years. Actas Dermosifiliogr 2022; 114:291-298. [PMID: 36529273 DOI: 10.1016/j.ad.2022.11.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2022] [Revised: 11/09/2022] [Accepted: 11/12/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Primary cutaneous lymphomas (PCL) are uncommon. Observations based on the first year of data from the Spanish Registry of Primary Cutaneous Lymphomas (RELCP, in its Spanish abbreviation) of the Spanish Academy of Dermatology and Venereology (AEDV) were published in February 2018. This report covers RELCP data for the first 5 years. PATIENTS AND METHODS RELCP data were collected prospectively and included diagnosis, treatments, tests, and the current status of patients. We compiled descriptive statistics of the data registered during the first 5 years. RESULTS Information on 2020 patients treated at 33 Spanish hospitals had been included in the RELCP by December 2021. Fifty-nine percent of the patients were men; the mean age was 62.2 years. The lymphomas were grouped into 4 large diagnostic categories: mycosis fungoides/Sézary syndrome, 1112 patients (55%); primary B-cell cutaneous lymphoma, 547 patients (27.1%); primary CD30+lymphoproliferative disorders, 222 patients (11%), and other T-cell lymphomas, 116 patients (5.8%). Nearly 75% of the tumors were registered in stage I. After treatment, 43.5% achieved complete remission and 27% were stable at the time of writing. Treatments prescribed were topical corticosteroids (1369 [67.8%]), phototherapy (890 patients [44.1%]), surgery (412 patients [20.4%]), and radiotherapy (384 patients [19%]). CONCLUSION The characteristics of cutaneous lymphomas in Spain are similar to those reported for other series. The large size of the RELCP registry at 5 years has allowed us to give more precise descriptive statistics than in the first year. This registry facilitates the clinical research of the AEDV's lymphoma interest group, which has already published articles based on the RELCP data.
Collapse
Affiliation(s)
- D Falkenhain-López
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España.
| | - C Muniesa
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - M T Estrach
- Departamento de Dermatología, Hospital Clínico, IDIBAPS, Universitario de Barcelona, Barcelona, España
| | - M Morillo-Andújar
- Departamento de Dermatología, Hospital Virgen del Rocío, Sevilla, España
| | - Y Peñate
- Departamento de Dermatología, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, España
| | - E Acebo
- Departamento de Dermatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, España
| | - R M Pujol
- Departamento de Dermatología, Hospital del Mar, Barcelona, España
| | - M P García-Muret
- Departamento de Dermatología, Hospital Santa Creu i Sant Pau, UAB Barcelona, Barcelona, España
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - S Medina
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, España
| | - R Botella-Estrada
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, España
| | - R Fernández de Misa
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, España
| | - M Blanes
- Departamento de Dermatología, Hospital General Universitario de Alicante, Alicante, España
| | - A Flórez
- Departamento de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España
| | - G Pérez-Paredes
- Departamento de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander Cantabria, España
| | - R Izu
- Departamento de Dermatología, Hospital Universitario de Basurto, Bilbao, Bizkaia, España
| | - I Yanguas
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, España
| | - E Silva-Díaz
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, España
| | - A Pérez-Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, España
| | - L Prieto-Torres
- Departamento de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España
| | - A Zayas
- Departamento de Dermatología, Hospital Universitario Dr. Peset, Valencia, España
| | - M E Parera-Amer
- Departamento de Dermatología, Hospital Universitario Son Llàtzer, Palma, Islas Baleares, España
| | - A Pérez
- Departamento de Dermatología, Hospital Universitario Nuestra Señora De Valme, Sevilla, España
| | - L Aspe
- Departamento de Dermatología, Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, España
| | - C Román
- Departamento de Dermatología, Hospital Universitario de Salamanca, Salamanca, España
| | - M P Sánchez-Caminero
- Departamento de Dermatología, Hospital General de Ciudad Real, Ciudad Real, España
| | - J Bassas-Vila
- Departamento de Dermatología, Hospital Germans Trias i Pujol, Barcelona, España
| | - J D Domínguez-Auñón
- Departamento de Dermatología, Hospital Universitario del Henares, Coslada, Madrid, España
| | - L Calzado
- Departamento de Dermatología, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, España
| | - M Navedo
- Departamento de Dermatología, Complejo Asistencial Universitario de León, León, España
| | - A Ortiz-Prieto
- Departamento de Dermatología, Hospital Puerta del Mar, Cádiz, España
| | - O Servitje
- Departamento de Dermatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España
| | - I Polo-Rodríguez
- Departamento de Dermatología, Hospital Universitario Príncipe de Asturias, Madrid, España
| | - I Torres
- Departamento de Dermatología, Hospital Universitario La Fe, Valencia, España
| | - M N Hernández-Hernández
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, España
| | - J Mitxelena-Eceiza
- Departamento de Dermatología Complejo Hospitalario de Navarra, Navarra, España
| | - A García-Vázquez
- Departamento de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, España
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, España; Departamento de Dermatología, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, España
| | - P L Ortiz-Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
| |
Collapse
|
8
|
Najidh S, Van der Sluijs Gelling AJ, Cozzio A, Dobos G, Bagot M, Beylot-Barry M, Guenova E, Nicolay J, Lima M, Ortiz-Romero PL, Papadavid E, Pujol R, Quaglino P, Stadler R, Wehkamp U, Whittaker S, Van Dongen JJM, Montero JF, Almeida J, Vermeer MH. Immunophenotypic identification and characterization of CTCL tumor cells in blood using standardized flow cytometry: a European multicenter study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00548-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, de Misa RF, Flórez A, Izu R, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00634-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
10
|
Mitsunaga K, Bagot M, Beylot-Barry M, Ram-Wolff C, Guenova E, Fassnacht C, Hodak E, Amitay I, Papadavid E, Jonak C, Porkert S, Scarisbrick J, Applewaite R, Nicolay J, Quaglino P, Sanches Jr J, Martins JC, Ortiz-Romero PL. Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas: an EORTC CLTF study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00599-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Moneva VG, Moreno MR, Alonso RA, Sánchez-Beato M, Peralto JLR, Pinilla MAP, Ortiz-Romero PL. Risk of progression of early-stage mycosis fungoides from RNA analysis. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00556-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Mendez VG, Merina A, Mitsunaga K, Barcena C, Arriscado CM, Ortiz-Romero PL. Lymph node infiltration in mycosis fungoides and Sézary syndrome: ultrasound features descriptive study. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00578-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
Alonso RA, Moreno MR, Díaz NG, García JFG, Roca LT, Caselles JB, Rodríguez MC, Company LC, Pinilla SMR, Mascuñano RC, Castro JT, Álvarez CMG, Peralto JLR, Díaz RR, Díez JPV, Ortiz-Romero PL, Pinilla MAP. Mycosis fungoides: molecular identity revealed by nanostring analysis. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00554-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
Ortiz-Romero PL, Jiménez LM, Muniesa C, Estrach T, Servitje O, de Misa RF, Gallardo F, Martín OS, Riveiro-Falkenbach E, Díaz NG, Vega R, Lora D, Postigo C, Jiménez B, Sánchez-Beato M, Vaqué JP, Peralto JLR, de la Cámara AG, De la Cruz J, Pinilla MAP. Final report of PIMTO-MF clinical trial: multicenter, phase II trial for treatment of early MF with topical pimecrolimus. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00641-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
15
|
Bagot M, Muller M, Kim YH, Ortiz-Romero PL, Zinzani PL, Beylot-Barry M, Dalle S, Jacobsen E, Combalia A, Huen A, Mehta-Shah N, Khodadoust MS, Viotti J, Paiva C, Porcu P. Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00590-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Muniz CAR, Vicente EJT, Andrés JAA, De Dios MAA, Alonso CV, Velázquez AS, Llorente CP, Ortiz-Romero PL. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00656-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
17
|
Velasco-Tamariz V, Falkenhain López D, Penalba-Torres M, Pinilla-Martín B, Puerta-Peña M, Palencia-Pérez SI, Ortiz-Romero PL. Drug reaction with eosinophilia and systemic symptoms in a 10-year-old boy sparing lichen planus lesions: an example of reverse isotopic response. J Eur Acad Dermatol Venereol 2022; 36:e537-e539. [PMID: 35143073 DOI: 10.1111/jdv.17998] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 01/19/2022] [Accepted: 02/04/2022] [Indexed: 11/28/2022]
Affiliation(s)
- V Velasco-Tamariz
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - D Falkenhain López
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - M Penalba-Torres
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - B Pinilla-Martín
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - M Puerta-Peña
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - S I Palencia-Pérez
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain
| |
Collapse
|
18
|
Falkenhain-López D, Fulgencio-Barbarin J, Puerta-Peña M, Montero-Menárguez J, Sánchez-Velázquez A, Ortiz-Romero PL. Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides. Br J Dermatol 2021; 186:363-365. [PMID: 34528240 DOI: 10.1111/bjd.20757] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Revised: 09/08/2021] [Accepted: 09/08/2021] [Indexed: 11/28/2022]
Abstract
Primary cutaneous T-cell lymphomas (CTCL) 1 are characterized by cutaneous clonal accumulation of T cells. Mycosis fungoides (MF) is the most common subtype. MF typically progresses slowly from early patch-plaque stage to advanced forms with tumours, erythroderma, and eventually nodal/visceral involvement. Sézary syndrome is characterized by leukemic involvement, lymphadenopathy and erythroderma 2 .
Collapse
Affiliation(s)
- D Falkenhain-López
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain
| | - J Fulgencio-Barbarin
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain
| | - M Puerta-Peña
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain
| | - J Montero-Menárguez
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain
| | - A Sánchez-Velázquez
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain
| | - P L Ortiz-Romero
- Dermatology Department of the Hospital Universitario 12 de Octubre, Av. Córdoba s/n 28041, Madrid, Spain.,Institute i+12. Medical School, University Complutense
| |
Collapse
|
19
|
Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. Br J Dermatol 2021; 185:1035-1044. [PMID: 34137025 DOI: 10.1111/bjd.20588] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND Brentuximab vedotin (BV) was approved as a therapy for mycosis fungoides (MF) based on the ALCANZA trial. Little real-world data, however, are available. OBJECTIVES To evaluate the efficacy and safety of BV in patients with MF/Sézary Syndrome (SS) with variable CD30 positivity in a real-world cohort and to explore potential predictors of response. METHODS Data from 72 patients with MF/SS across nine EORTC (European Organization for Research and Treatment of Cancer) centres were included. The primary endpoint was to evaluate the proportion of patients with: overall response (ORR), ORR lasting over 4 months (ORR4), time to response (TTR), response duration (RD), progression-free survival (PFS) and time to next treatment (TTNT). Secondary aims included a safety evaluation and the association of clinicopathological features with ORR, RD and TTNT. RESULTS All 72 patients had received at least one systemic treatment. ORR was achieved in 45 of 67; ORR4 in 28 of 67 with a median TTR of 8 weeks [interquartile range (IQR) 5·5-14] and with a median RD of 9 months (IQR 3·4-14). Median PFS was 7 months (IQR 2-12) and median TTNT was 30 days (6-157·5). Patient response, RD, PFS and TTNT were not associated with any clinicopathological characteristics. In the MF group, patients with stage IIB/III vs. IV achieved longer PFS and had a higher percentage of ORR4. There was a statistically significant association between large-cell transformation and skin ORR (P = 0·03). ORR4 was more frequently achieved in patients without lymph node involvement (P = 0·04). CONCLUSIONS BV is an effective option for patients with MF/SS, including those with variable CD30 positivity, large-cell transformation, SS, longer disease duration and who have been treated previously with several therapies.
Collapse
Affiliation(s)
- E Papadavid
- 1st and 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - E Kapniari
- 1st and 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - V Pappa
- 1st and 2nd Propaedeutic Department, Hematology Units, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - V Nikolaou
- 1st and 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - T Iliakis
- 1st and 2nd Propaedeutic Department, Hematology Units, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - M Dalamaga
- 1st Department of Biological Chemistry, National and Kapodistrian University of Athens Medical School, Athens, Greece
| | - C Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - S Porkert
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - S Engelina
- Division of Dermatology, Tel Aviv University, Israel
| | - P Quaglino
- Division of Dermatology, Tel Aviv University, Israel
| | - P L Ortiz-Romero
- Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy
| | - C Vico
- Department of Dermatology, 12 de Octubre Hospital, Medical School, University Compultense, Madrid, Spain
| | - A Cozzio
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - F Dimitriou
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - R Guiron
- Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Tel Aviv University, Israel
| | - E Guenova
- Department of Dermatology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.,Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - E Hodak
- Division of Dermatology, Tel Aviv University, Israel
| | - M Bagot
- Dermatology Department, APHP, Saint-Louis Hospital, Université de Paris, Paris, France.,Inserm U976, Paris, France
| | - J Scarisbrick
- Department of Dermatology, Centre for Rare Diseases, University Hospital Birmingham, Birmingham, UK
| |
Collapse
|
20
|
Ortiz-Romero PL. The time for new biomarkers in mycosis fungoides/Sézary syndrome is here. Br J Dermatol 2021; 185:250-251. [PMID: 34096050 DOI: 10.1111/bjd.20491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 04/07/2021] [Indexed: 11/29/2022]
Affiliation(s)
- P L Ortiz-Romero
- Service of Dermatology, Hospital 12 de Octubre. Institute i+12, CIBERONC, Medical School, University Complutense, Madrid, Spain
| |
Collapse
|
21
|
Sánchez-Velázquez A, Bauer-Alonso A, Estrach T, Vega-Díez D, Garcia-Muret P, Haya L, Peñate Y, Acebo E, Fernández de Misa R, Blanes M, Suh-Oh HJ, Izu R, Silva-Díaz E, Sarriugarte J, Román-Curto C, Botella-Estrada R, Mateu-Puchades A, Prieto-Torres L, Morillas V, Morillo M, Sánchez-Caminero P, Calzado L, Pérez-Ferriols A, Pérez A, Domínguez JD, Navedo M, Muniesa C, Combalia A, Arroyo-Andrés J, Descalzo MA, García-Doval I, Ortiz-Romero PL. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2021; 35:e624-e626. [PMID: 34062018 PMCID: PMC8242655 DOI: 10.1111/jdv.17430] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- A Sánchez-Velázquez
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| | - A Bauer-Alonso
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - T Estrach
- Department of Dermatology, IDIBAPS, Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - D Vega-Díez
- Department of Dermatology, Hospital Universitario Príncipe de Asturias, Madrid, Spain
| | - P Garcia-Muret
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - L Haya
- Department of Dermatology, Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas, Spain
| | - E Acebo
- Department of Dermatology, Hospital Universitario de Cruces, Bizkaia, Spain
| | - R Fernández de Misa
- Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - M Blanes
- Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
| | - H J Suh-Oh
- SERGAS-UVIGO, DIPO Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Pontevedra, Spain
| | - R Izu
- Department of Dermatology, Hospital Universitario Basurto, Bizkaia, Spain
| | - E Silva-Díaz
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - J Sarriugarte
- Department of Dermatology, Complejo Hospitalario de Navarra, Navarra, Spain
| | - C Román-Curto
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - R Botella-Estrada
- Department of Dermatology, Hospital Universitario la Fé, Valencia, Spain
| | - A Mateu-Puchades
- Department of Dermatology, Hospital Universitario Dr. Peset, Valencia, Spain
| | - L Prieto-Torres
- Department of Dermatology, Hospital Universitario Lozano Blesa, Valencia, Spain
| | - V Morillas
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Zaragoza, Spain
| | - M Morillo
- Department of Dermatology, Hospital Universitario Virgen de Rocío, Barcelona, Spain
| | - P Sánchez-Caminero
- Department of Dermatology, Hospital General Universitario de Ciudad Real, Sevilla, Spain
| | - L Calzado
- Department of Dermatology, Hospital Universitario de Torrejón, Ciudad Real, Spain
| | - A Pérez-Ferriols
- Department of Dermatology, Hospital General Universitario de Valencia, Madrid, Spain
| | - A Pérez
- Department of Dermatology, Hospital Universitario Nuestra Señora De Valme, Valencia, Spain
| | - J D Domínguez
- Department of Dermatology, Hospital Universitario del Henares, Sevilla, Spain
| | - M Navedo
- Department of Dermatology, Complejo Asistencial Universitario de León, Madrid, Spain
| | - C Muniesa
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - A Combalia
- Department of Dermatology, IDIBAPS, Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - J Arroyo-Andrés
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| | - M A Descalzo
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain
| | - I García-Doval
- Unidad de Investigación, Fundación Piel Sana AEDV, León, Spain.,Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Institute i+12, CIBERONC, Medical School, Hospital Universitario 12 de Octubre, University Complutense, Madrid, Spain
| |
Collapse
|
22
|
Hodak E, Sherman S, Papadavid E, Bagot M, Querfeld C, Quaglino P, Prince HM, Ortiz-Romero PL, Stadler R, Knobler R, Guenova E, Estrach T, Patsatsi A, Leshem YA, Prague-Naveh H, Berti E, Alberti-Violetti S, Cowan R, Jonak C, Nikolaou V, Mitteldorf C, Akilov O, Geskin L, Matin R, Beylot-Barry M, Vakeva L, Sanches JA, Servitje O, Weatherhead S, Wobser M, Yoo J, Bayne M, Bates A, Dunnill G, Marschalko M, Buschots AM, Wehkamp U, Evison F, Hong E, Amitay-Laish I, Stranzenbach R, Vermeer M, Willemze R, Kempf W, Cerroni L, Whittaker S, Kim YH, Scarisbrick JJ. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. Br J Dermatol 2021; 184:524-531. [PMID: 32574377 DOI: 10.1111/bjd.19303] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/30/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Early-stage mycosis fungoides (MF) includes involvement of dermatopathic lymph nodes (LNs) or early lymphomatous LNs. There is a lack of unanimity among current guidelines regarding the indications for initial staging imaging in early-stage presentation of MF in the absence of enlarged palpable LNs. OBJECTIVES To investigate how often imaging is performed in patients with early-stage presentation of MF, to assess the yield of LN imaging, and to determine what disease characteristics promoted imaging. METHODS A review of clinicopathologically confirmed newly diagnosed patients with cutaneous patch/plaque (T1/T2) MF from PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) data. RESULTS PROCLIPI enrolled 375 patients with stage T1/T2 MF: 304 with classical MF and 71 with folliculotropic MF. Imaging was performed in 169 patients (45%): 83 with computed tomography, 18 with positron emission tomography-computed tomography and 68 with ultrasound. Only nine of these (5%) had palpable enlarged (≥ 15 mm) LNs, with an over-representation of plaques, irrespectively of the 10% body surface area cutoff that distinguishes T1 from T2. Folliculotropic MF was not more frequently imaged than classical MF. Radiologically enlarged LNs (≥ 15 mm) were detected in 30 patients (18%); only seven had clinical lymphadenopathy. On multivariate analysis, plaque presentation was the sole parameter significantly associated with radiologically enlarged LNs. Imaging of only clinically enlarged LNs upstaged 4% of patients (seven of 169) to at least IIA, whereas nonselective imaging upstaged another 14% (24 of 169). LN biopsy, performed in eight of 30 patients, identified N3 (extensive lymphomatous involvement) in two and N1 (dermatopathic changes) in six. CONCLUSIONS Physical examination was a poor determinant of LN enlargement or involvement. Presence of plaques was associated with a significant increase in identification of enlarged or involved LNs in patients with early-stage presentation of MF, which may be important when deciding who to image. Imaging increases the detection rate of stage IIA MF, and identifies rare cases of extensive lymphomatous nodes, upstaging them to advanced-stage IVA2.
Collapse
Affiliation(s)
- E Hodak
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S Sherman
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Papadavid
- Athens University Medical School, Athens, Greece
| | - M Bagot
- Hospital St Louis, Paris, France
| | - C Querfeld
- City of Hope National Medical Center and Beckman Research Institute, Duarte, CA, USA
| | - P Quaglino
- Dermatologic Clinic, University of Turin Medical School, Turin, Italy
| | - H M Prince
- Sir Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital 12 de Octubre, Medical School, University Complutense, Madrid, Spain
| | - R Stadler
- Johannes Wesling University Medical Centre, Minden, Germany
| | - R Knobler
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - E Guenova
- University Hospital Zurich, Zurich, Switzerland
| | - T Estrach
- Hospital Clinico, University of Barcelona, Barcelona, Spain
| | - A Patsatsi
- Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
| | - Y A Leshem
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Prague-Naveh
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - E Berti
- University of Milan, Milan, Italy
| | | | - R Cowan
- Christie Hospital, Manchester, UK
| | - C Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - V Nikolaou
- Athens University Medical School, Athens, Greece
| | - C Mitteldorf
- HELIOS Klinikum Hildesheim GmbH, University Medical Centre Göttingen, Göttingen, Germany
| | - O Akilov
- University of Pittsburgh School of Medicine, Pennsylvania, PA, USA
| | - L Geskin
- University of Columbia, New York, NY, USA
| | - R Matin
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | | | - L Vakeva
- Helsinki University Central Hospital, Helsinki, Finland
| | - J A Sanches
- University of São Paulo Medical School, São Paulo, SP, Brazil
| | - O Servitje
- Hospital Universatari de Bellvitge, Barcelona, Spain
| | | | - M Wobser
- University Hospital Wuerzburg, Wuerzburg, Germany
| | - J Yoo
- University Hospital Birmingham, Birmingham, UK
| | | | - A Bates
- University Hospital Southampton, Southampton, UK
| | - G Dunnill
- University Hospital Bristol, Bristol, UK
| | | | | | - U Wehkamp
- University Hospital Kiel, Kiel, Germany
| | - F Evison
- University Hospital Birmingham, Birmingham, UK
| | - E Hong
- Stanford University Medical Center, Stanford, CA, USA
| | - I Amitay-Laish
- Division of Dermatology, Rabin Medical Center - Beilinson Hospital, Petach Tikva; affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - R Stranzenbach
- Johannes Wesling University Medical Centre, Minden, Germany
| | - M Vermeer
- Leiden University Medical Centre, Leiden, the Netherlands
| | - R Willemze
- Leiden University Medical Centre, Leiden, the Netherlands
| | - W Kempf
- Kempf and PFlatz, Histologische Diagnostik, Zurich, Switzerland
| | - L Cerroni
- Department of Dermatology, Research Unit Dermatopathology, Medical University of Graz, Graz, Austria
| | | | - Y H Kim
- Stanford University Medical Center, Stanford, CA, USA
| | | |
Collapse
|
23
|
Kempf W, Mitteldorf C, Battistella M, Willemze R, Cerroni L, Santucci M, Geissinger E, Jansen P, Vermeer MH, Marschalko M, Papadavid E, Piris MA, Ortiz-Romero PL, Novelli M, Paulli M, Quaglino P, Ranki A, Rodríguez Peralto JL, Wobser M, Auschra B, Robson A. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features. J Eur Acad Dermatol Venereol 2020; 35:658-668. [PMID: 32997839 DOI: 10.1111/jdv.16969] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Accepted: 09/10/2020] [Indexed: 01/06/2023]
Abstract
BACKGROUND Cutaneous peripheral T-cell lymphoma, not otherwise specified (PTL NOS) is an aggressive, but poorly characterized neoplasm. OBJECTIVES The European Organization for Research and Treatment of Cancer cutaneous lymphoma taskforce (EORTC CLTF) investigated 33 biopsies of 30 patients with primary cutaneous PTL NOS to analyse their clinical, histological, immunophenotypic features and outcome. METHODS Retrospective analysis of clinical data and histopathological features by an expert panel. RESULTS Cutaneous PTL NOS manifested clinically either with solitary or disseminated rapidly grown ulcerated tumours or disseminated papulo-nodular lesions. Histologically, a mostly diffuse or nodular infiltrate in the dermis and often extending into the subcutis was found. Epidermotropism was rarely present and only mild and focal. Unusual phenotypes were frequent, e.g. CD3+ /CD4- /CD8- and CD3+ /CD4+ /CD8+ . Moreover, 18% of the cases exhibited an aberrant expression of the B-cell marker CD20 by the tumour cells. All solitary tumours were located on the limbs and presented a high expression of GATA-3 but this did not correlate with outcome and therefore could not serve as a prognostic factor. The prognosis was shown to be generally poor with 10 of 30 patients (33%) dying of lymphoma within the follow-up of 36 months (mean value; range 3-144). The survival rates were 61% after 3 years (CI, 43-85%) and 54% after 5 years (CI, 36-81%). Small to medium-sized morphology of tumour cells was associated with a better outcome than medium to large or large tumour cells. Age, gender, clinical stage, CD4/CD8 phenotype and GATA-3 expression were not associated with prognosis. Chemotherapy was the most common treatment modality, but surgical excision and/or radiotherapy may represent an appropriate first-line treatment for solitary lesions. CONCLUSIONS Cutaneous PTL NOS shows an aggressive course in most patients independent of initial presentation, age and phenotype. Cytomorphology was identified as a prognostic factor. The data indicate a need for more effective treatment modalities in PTL NOS.
Collapse
Affiliation(s)
- W Kempf
- Histologische Diagnostik, Kempf und Pfaltz, Zürich, Switzerland.,Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | - C Mitteldorf
- Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany
| | - M Battistella
- Department of Pathology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, INSERM U976, Paris, France
| | - R Willemze
- Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
| | - L Cerroni
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - M Santucci
- Department of Health Sciences, University of Florence School of Human Health Sciences, Florence, Italy.,Division of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy
| | - E Geissinger
- Institute of Pathology, University of Würzburg, Würzburg, Germany
| | - P Jansen
- Department of Clinical Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - M H Vermeer
- Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
| | - M Marschalko
- Department of Dermatology and Venerology, Semmelweis Medical University, Budapest, Hungary
| | - E Papadavid
- Department of Dermatology-Venereology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece
| | - M A Piris
- Department of Pathology, Fundacion Jimenez Diaz, CIBERONC, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital 12 de Octubre, Medical School, Institute i+12, University Complutense, Madrid, Spain
| | - M Novelli
- Cutaneous Immunopathology Laboratory, Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
| | - M Paulli
- Department of Molecular Pathology, University of Pavia, Pavia, Italy.,Department of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - P Quaglino
- Dermatologic Clinic, Dept Medical Sciences, University of Turin Medical School, Torino, Italy
| | - A Ranki
- Department of Dermatology and Allergology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
| | - J L Rodríguez Peralto
- Department of Pathology, Hospital Universitario 12 de Octubre, Universidad, Complutense, Instituto de Investigación I+12, Madrid, Spain
| | - M Wobser
- Department of Dermatology, University of Würzburg, Würzburg, Germany
| | - B Auschra
- Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich, Switzerland
| | - A Robson
- Institute of Oncology, Lisbon, Portugal.,LDPath, London, UK
| |
Collapse
|
24
|
Molloy K, Vico C, Ortiz-Romero PL, Scarisbrick JJ. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome. Br J Dermatol 2020; 184:978-981. [PMID: 33314065 DOI: 10.1111/bjd.19720] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Revised: 12/08/2020] [Accepted: 12/08/2020] [Indexed: 11/28/2022]
Affiliation(s)
- K Molloy
- University Hospital Birmingham, Birmingham, UK
| | - C Vico
- Hospital 12 de Octubre. Institute i+12. CIBERONC. Medical School, University Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Hospital 12 de Octubre. Institute i+12. CIBERONC. Medical School, University Complutense, Madrid, Spain
| | | |
Collapse
|
25
|
Rubio-Muniz CA, Puerta-Peña M, Falkenhain-López D, Arroyo-Andrés J, Agud-Dios M, Rodriguez-Peralto JL, Ortiz-Romero PL, Rivera-Díaz R. The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases. J Eur Acad Dermatol Venereol 2020; 34:e574-e576. [PMID: 32526040 PMCID: PMC7307079 DOI: 10.1111/jdv.16734] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- C A Rubio-Muniz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Puerta-Peña
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - D Falkenhain-López
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J Arroyo-Andrés
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Agud-Dios
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - R Rivera-Díaz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
26
|
Puerta-Peña M, Fulgencio-Barbarin J, Falkenhain D, Ortiz-Romero PL, Monsálvez-Honrubia V. Answer to Photoquiz Red streaks arising from the periumbilical area in a mirror-like pattern. Neth J Med 2020; 78:211. [PMID: 32641552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
- M Puerta-Peña
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | | | | | |
Collapse
|
27
|
Puerta-Peña M, Fulgencio-Barbarin J, Falkenhain D, Ortiz-Romero PL, Monsálvez-Honrubia V. Red streaks arising from the periumbilical area in a mirror-like pattern. Neth J Med 2020; 78:0. [PMID: 32641551] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
- M Puerta-Peña
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | | | | | | |
Collapse
|
28
|
Affiliation(s)
- D Falkenhain-López
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Agud-Dios
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P L Ortiz-Romero
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Sánchez-Velázquez
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
29
|
Fernández-de-Misa R, Hernández-Machín B, Combalía A, García Muret MP, Servitje O, Muniesa C, Gallardo F, Pujol RM, Martí RM, Ortiz-Brugués A, Maroñas-Jiménez L, Ortiz-Romero PL, Blanch Rius L, Izu R, Román C, Cañueto J, Blanes M, Morillo M, Bastida J, Peñate Y, Pérez Gala S, Espinosa Lara P, Pérez Gil A, Estrach T. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J Eur Acad Dermatol Venereol 2019; 34:762-768. [PMID: 31591786 DOI: 10.1111/jdv.16006] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 09/25/2019] [Indexed: 11/29/2022]
Abstract
BACKGROUND Reliable prognostic factors for patients with primary cutaneous anaplastic large cell lymphoma (PCALCL) are lacking. OBJECTIVE To identify prognostic factors for specific survival in patients with PCALCL. METHODS Using the convenience sampling method, patients with PCALCL diagnosed from May 1986 to August 2017 in 16 University Departments were retrospectively reviewed. RESULTS One hundred eight patients were included (57 males). Median age at diagnosis was 58 years. All of them showed T1-3N0M0 stages. Seventy per cent of the cases presented with a solitary lesion, mostly at the limbs. Complete response rate after first-line treatment was 87%, and no advantage was observed for any of them (surgery, radiotherapy, chemotherapy or other approaches). Nodal and visceral progression rate was 11% and 2%, respectively. 5-year specific survival (SSV) reached 93%; 97% for T1 patients and 84% for T2/T3 patients (P = 0.031). Five-year SSV for patients developing early cutaneous relapse was 64%; for those with late or no relapse, 96% (P = 0.001). Estimated median SSV for patients showing nodal progression was 103 months (95% CI: 51-155 months); for patients without nodal progression, estimated SSV did not reach the median (P < 0.001). Nodal progression was an independent predictive parameter for shorter survival (P = 0.011). CONCLUSION Multiple cutaneous lesions at presentation, early skin relapse and nodal progression portrait worse prognosis in patients with PCALCL.
Collapse
Affiliation(s)
- R Fernández-de-Misa
- Department of Dermatology and Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - B Hernández-Machín
- Department of Dermatology, Sefton Suite, DMC Healthcare, NHS Trust Liverpool, Liverpool, UK
| | - A Combalía
- Department of Dermatology, Hospital Clínico, University of Barcelona, Barcelona, Spain
| | - M P García Muret
- Department of Dermatology, Hospital Santa Creu i Sant Pau, UAB, Barcelona, Spain
| | - O Servitje
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - C Muniesa
- Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL, Barcelona, Spain
| | - F Gallardo
- Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - R M Pujol
- Department of Dermatology, Hospital del Mar, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - R M Martí
- Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain.,Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - A Ortiz-Brugués
- Department of Dermatology, Hospital Univeritari Arnau de Vilanova, IRBLleida, Lleida, Spain
| | - L Maroñas-Jiménez
- Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.,Department of Dermatology, Hospital Universitario 12 de Octubre, i+12 Research Institute, Universidad Complutense, Madrid, Spain
| | - L Blanch Rius
- Department of Dermatology, Hospital de Basurto, Bilbao, Spain
| | - R Izu
- Department of Dermatology, Hospital de Basurto, Bilbao, Spain
| | - C Román
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - J Cañueto
- Department of Dermatology, Hospital Universitario de Salamanca, Salamanca, Spain
| | - M Blanes
- Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
| | - M Morillo
- Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J Bastida
- Department of Dermatology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de G.C, Spain
| | - S Pérez Gala
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - P Espinosa Lara
- Department of Dermatology, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
| | - A Pérez Gil
- Department of Dermatology, Hospital Virgen de Valme, Sevilla, Spain
| | - T Estrach
- Department of Dermatology, Hospital Clínico, IDIBAPS, University of Barcelona, Barcelona, Spain
| |
Collapse
|
30
|
Pérez C, Mondéjar R, García-Díaz N, Cereceda L, León A, Montes S, Durán Vian C, Pérez Paredes MG, González-Morán A, Alegre de Miguel V, Sanz Anquela JM, Frias J, Limeres MA, González LM, Martín Dávila F, Beltrán M, Mollejo M, Méndez JR, González MA, González García J, López R, Gómez A, Izquierdo F, Ramos R, Camacho C, Rodriguez-Pinilla SM, Martínez N, Vaqué JP, Ortiz-Romero PL, Piris MA. Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. Br J Dermatol 2019; 182:147-155. [PMID: 31049933 DOI: 10.1111/bjd.18098] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND The malignant mechanisms that control the development of cutaneous T-cell lymphoma (CTCL) are beginning to be identified. Recent evidence suggests that disturbances in specific intracellular signalling pathways, such as RAS-mitogen-activated protein kinase, T-cell receptor (TCR)-phospholipase C gamma 1 (PLCG1)-nuclear factor of activated T cells (NFAT) and Janus kinase (JAK)-signal transducer and activator of transcription (STAT), may play an essential role in the pathogenesis of CTCL. OBJECTIVES To investigate the mechanisms controlling disease development and progression in mycosis fungoides (MF), the most common form of CTCL. METHODS We collected 100 samples that were submitted for diagnosis of, or a second opinion regarding, MF between 2001 and 2018, 80% of which were in the early clinical stages of the disease. Formalin-fixed paraffin-embedded tissues were used for histological review and to measure the expression by immunohistochemistry of surrogate markers of activation of the TCR-PLCG1-NFAT, JAK-STAT and NF-κB pathways. Folliculotropism and large-cell transformation were also examined. RESULTS NFAT and nuclear factor kappa B (NF-κB) markers showed a comparable activation status in early and advanced stages, while STAT3 activation was more frequent in advanced stages and was associated with large-cell transformation. Consistently with this observation, STAT3 activation occurred in parallel with MF progression in two initially MF-negative cases. A significant association of NFAT with NF-κB markers was also found, reflecting a common mechanism of activation in the two pathways. Genomic studies identified nine mutations in seven genes known to play a potential role in tumorigenesis in T-cell leukaemia/lymphoma, including PLCG1, JAK3 and STAT3, which underlies the activation of these key cell-survival pathways. A higher mutational allele frequency was detected in advanced stages. CONCLUSIONS Our results show that STAT3 is activated in advanced cases and is associated with large-cell transformation, while the activation of NFAT and NF-κB is maintained throughout the disease. These findings could have important diagnostic and therapeutic implications. What's already known about this topic? Mycosis fungoides is characterized by a clonal expansion of T cells in the skin. The mechanisms controlling disease development and progression are not fully understood. What does this study add? An association of the nuclear factor of activated T cells and nuclear factor kappa B pathways was found, which could reflect a common mechanism of activation. These pathways were activated in early and advanced stages at the same level. Signal transducer and activator of transcription 3 activation was associated with large-cell transformation and was more frequent in advanced stages. A genomic analysis of cutaneous T-cell lymphoma-associated genes was performed. Nine mutations were detected. What is the translational message? These results could have important implications for the treatment of MF in the near future.
Collapse
Affiliation(s)
- C Pérez
- Translational Hematopathology, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain.,Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain
| | - R Mondéjar
- Translational Hematopathology, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain.,Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Service of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
| | - N García-Díaz
- Departamento de Biología Molecular, Universidad de Cantabria, Infección, Inmunidad y Patología Digestive, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - L Cereceda
- Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Service of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
| | - A León
- Pathology Service, Marqués de Valdecilla University Hospital, Santander, Spain
| | - S Montes
- Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Pathology Service, Marqués de Valdecilla University Hospital, Santander, Spain
| | - C Durán Vian
- Dermatology Service, Marqués de Valdecilla University Hospital, Santander, Spain
| | - M G Pérez Paredes
- Dermatology Service, Marqués de Valdecilla University Hospital, Santander, Spain
| | - A González-Morán
- Dermatology Service, Complejo Hospitalario de Ávila, Ávila, Spain
| | - V Alegre de Miguel
- Dermatology Service, Hospital General Universitario de Valencia, Valencia, Spain
| | - J M Sanz Anquela
- Cancer Registry and Pathology Department, Hospital Universitario Príncipe de Asturias and Department of Medicine and Medical Specialties, Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain
| | - J Frias
- Dermatology Service, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
| | - M A Limeres
- Pathology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Gran Canaria, Canarias, Spain
| | - L M González
- Pathology Service, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - F Martín Dávila
- Pathology Service, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - M Beltrán
- Pathology Service, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - M Mollejo
- Pathology Service, Complejo Hospitalario de Toledo, Toledo, Spain
| | - J R Méndez
- Pathology Service, Centro Médico de Asturias, Asturias, Spain
| | - M A González
- Pathology Service, Hospital San Pedro de Alcántara, Cáceres, Spain
| | - J González García
- Pathology Service, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - R López
- Pathology Service, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
| | - A Gómez
- Pathology Service, Hospital de la Marina Baixa, Alicante, Spain
| | - F Izquierdo
- Pathology Service, Complejo Asistencial Universitario de León, León, Spain
| | - R Ramos
- Pathology Service, University Hospital Son Espases, Palma de Mallorca, Spain
| | - C Camacho
- Pathology Service, C.H.U. Insular - Materno Infantil, Gran Canarias, Spain
| | - S M Rodriguez-Pinilla
- Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Service of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
| | - N Martínez
- Translational Hematopathology, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain.,Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain
| | - J P Vaqué
- Departamento de Biología Molecular, Universidad de Cantabria, Infección, Inmunidad y Patología Digestive, Instituto de Investigación Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - P L Ortiz-Romero
- Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Dermatology Service, Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense, Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain
| | - M A Piris
- Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.,Service of Pathology, Fundación Jiménez Díaz University Hospital, Madrid, Spain
| |
Collapse
|
31
|
Affiliation(s)
- T Estrach
- Servicio de Dermatologia, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, España.
| | - O Servitje
- Servicio de Dermatología, Hospital Universitari de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat España
| | - P L Ortiz-Romero
- Servicio de Dermatologia, Hospital 12 de Octubre, Instituto i+12, Facultad de Medicina, Universidad Complutense, Madrid, España
| |
Collapse
|
32
|
Maroñas-Jiménez L, Estrach T, Gallardo F, Pérez A, Andrés Borja H, Servitje O, Pérez Gala S, Linares Barrio M, Jiménez Gallo D, Sanz-Bueno J, Lora D, Monsálvez V, Ortiz-Romero PL. Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. Br J Dermatol 2018; 178:e273-e274. [PMID: 29150837 DOI: 10.1111/bjd.16128] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- L Maroñas-Jiménez
- Department of Dermatology, Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense, Madrid, Spain
| | - T Estrach
- Department of Dermatology, Hospital Clínic-Universitat de Barcelona IDIBAPS, Barcelona, Spain
| | - F Gallardo
- Department of Dermatology, Hospital Del Mar, Barcelona, Spain
| | - A Pérez
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
| | - H Andrés Borja
- Department of Dermatology, Hospital Universitario Donostia, San Sebastián, Spain
| | - O Servitje
- Department of Dermatology, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - S Pérez Gala
- Department of Dermatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - M Linares Barrio
- Department of Dermatology, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - D Jiménez Gallo
- Department of Dermatology, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - J Sanz-Bueno
- Department of Dermatology, Hospital Universitario Rey Juan Carlos, Madrid, Spain
| | - D Lora
- Clinical Research Unit, IMAS12-CIBERESP, Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense, Madrid, Spain
| | - V Monsálvez
- Department of Dermatology, Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario, 12 de Octubre, Instituto de Investigación i + 12, Universidad Complutense, Madrid, Spain
| |
Collapse
|
33
|
Affiliation(s)
- L Maroñas-Jiménez
- Department of Dermatology, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Universidad Complutense, Avenida de Córdoba S/N 28041, Madrid, Spain
| | - P L Ortiz-Romero
- Department of Dermatology, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12, Universidad Complutense, Avenida de Córdoba S/N 28041, Madrid, Spain.,Centro de Investigación Biomédica en Red de Cáncer, 28029, Madrid, Spain
| |
Collapse
|
34
|
Fernández-de-Misa R, Hernández-Machín B, Servitje O, Valentí-Medina F, Maroñas-Jiménez L, Ortiz-Romero PL, Sánchez Schmidt J, Pujol RM, Gallardo F, Pau-Charles I, García Muret MP, Pérez Gala S, Román C, Cañueto J, Blanch Rius L, Izu R, Ortiz-Brugués A, Martí RM, Blanes M, Morillo M, Sánchez P, Peñate Y, Bastida J, Pérez Gil A, Lopez-Lerma I, Muniesa C, Estrach T. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol 2017; 43:137-143. [DOI: 10.1111/ced.13256] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2016] [Indexed: 11/30/2022]
Affiliation(s)
- R. Fernández-de-Misa
- Department of Dermatology and Research Unit; Hospital Universitario Nuestra Señora de Candelaria; Santa Cruz de Tenerife Spain
| | - B. Hernández-Machín
- Department of Dermatology; Clínica Buenaderma; Las Palmas de Gran Canaria Spain
| | - O. Servitje
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - F. Valentí-Medina
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - L. Maroñas-Jiménez
- Department of Dermatology; Hospital Universitario 12 de Octubre, i+12 Research Institute; Universidad Complutense Madrid; Madrid Spain
| | - P. L. Ortiz-Romero
- Department of Dermatology; Hospital Universitario 12 de Octubre, i+12 Research Institute; Universidad Complutense Madrid; Madrid Spain
| | - J. Sánchez Schmidt
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - R. M. Pujol
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - F. Gallardo
- Department of Dermatology; Hospital del Mar; Universitat Autónoma de Barcelona; Barcelona Spain
| | - I. Pau-Charles
- Department of Dermatology; Hospital Clínico; University of Barcelona; IDIBAPS; Barcelona Spain
| | - M. P. García Muret
- Department of Dermatology; Hospital Santa Creu i Sant Pau; UAB; Barcelona Spain
| | - S. Pérez Gala
- Department of Dermatology; Hospital Universitario Ramón y Cajal; Madrid Spain
| | - C. Román
- Department of Dermatology; Hospital Universitario de Salamanca; Salamanca Spain
| | - J. Cañueto
- Department of Dermatology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Blanch Rius
- Department of Dermatology; Hospital de Basurto; Bilbao Spain
| | - R. Izu
- Department of Dermatology; Hospital de Basurto; Bilbao Spain
| | - A. Ortiz-Brugués
- Department of Dermatology; IRBLleida, Hospital Universitari Arnau de Vilanova; Lleida Spain
| | - R. M. Martí
- Department of Dermatology; IRBLleida, Hospital Universitari Arnau de Vilanova; Lleida Spain
| | - M. Blanes
- Department of Dermatology; Hospital General Universitario de Alicante; Alicante Spain
| | - M. Morillo
- Department of Dermatology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - P. Sánchez
- Department of Dermatology; Hospital de León; León Spain
| | - Y. Peñate
- Department of Dermatology; Complejo Hospitalario Universitario Insular Materno-Infantil; Gran Canaria, Las Palmas de Gran Canaria Spain
| | - J. Bastida
- Department of Dermatology; Hospital Universitario Dr. Negrín; Las Palmas de Gran Canaria Spain
| | - A. Pérez Gil
- Department of Dermatology; Hospital Virgen de Valme; Sevilla Spain
| | - I. Lopez-Lerma
- Department of Dermatology; Hospital Universitari Vall d'Hebron; Barcelona Spain
| | - C. Muniesa
- Department of Dermatology; Hospital Universitari de Bellvitge; IDIBELL; Barcelona Spain
| | - T. Estrach
- Department of Dermatology; Hospital Clínico; University of Barcelona; IDIBAPS; Barcelona Spain
| |
Collapse
|
35
|
Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, Burillo-Martinez S, Zarco-Olivo C, Rodriguez-Peralto JL, Ortiz-Romero PL. Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol 2017; 178:786-789. [PMID: 28222222 DOI: 10.1111/bjd.15400] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/15/2017] [Indexed: 11/29/2022]
Abstract
A 65-year-old pluripathological woman attended our hospital with a cutaneous eruption of sudden appearance after vancomycin treatment. She presented targetoid lesions affecting approximately 25-30% of her body surface, large erosions with mucosal lesions and positive Nikolsky sign. Under the initial clinical suspicion of toxic epidermal necrolysis (TEN), and considering the recent literature of successful use of etanercept in these cases, she was treated with a single dose of this antitumour necrosis factor (anti-TNF) agent. Subsequently, the exanthema progression stopped and resolution of the lesions happened in a few days. Later on, histopathology revealed a subepidermal blister with dense neutrophilic infiltrate and linear deposits of immunoglobulin A (IgA) on the dermoepidermal junction, allowing us to establish the diagnosis of drug-induced linear IgA dermatosis mimicking TEN. Linear IgA dermatosis can have severe clinical manifestations, even mimicking TEN, and can have high mortality, especially in drug-induced cases. We have not found any other report of linear IgA dermatosis treated with etanercept in the English literature. Anti-TNF medications could represent useful therapeutic alternatives in this dermatosis.
Collapse
Affiliation(s)
- M Prieto-Barrios
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - V Velasco-Tamariz
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - F Tous-Romero
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - S Burillo-Martinez
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - C Zarco-Olivo
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - J L Rodriguez-Peralto
- Departments of Pathology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| | - P L Ortiz-Romero
- Departments of Dermatology, Hospital Universitario 12 de Octubre, I + 12 Research Institute, Universidad Complutense, Madrid, Spain
| |
Collapse
|
36
|
Ortiz-Romero PL. Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas. Br J Dermatol 2016; 175:246-7. [PMID: 27535600 DOI: 10.1111/bjd.14783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- P L Ortiz-Romero
- Servicio de Dermatología, Hospital 12 de Octubre, Universidad Complutense, Instituto i + 12, Madrid, Spain.
| |
Collapse
|
37
|
Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol 2016; 175:80-8. [PMID: 26836950 DOI: 10.1111/bjd.14427] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/25/2016] [Indexed: 01/13/2023]
Abstract
BACKGROUND Quisinostat is a hydroxamate, second-generation, orally available pan-histone deacetylase inhibitor. OBJECTIVES To evaluate the efficacy and safety of oral quisinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL). METHODS Patients received quisinostat 8 mg or 12 mg on days 1, 3 and 5 of each week in 21-day treatment cycles. Primary efficacy end point was cutaneous response rate (RR) based on the modified Severity Weighted Assessment Tool (mSWAT). Secondary end points included global RR, duration of response (DOR) in skin, progression-free survival (PFS), pruritus relief, safety and pharmacodynamic markers. RESULTS Eight of 26 (25 evaluable) patients achieved ≥ 50% reduction in mSWAT score at least once, with confirmed cutaneous response in six (RR 24%). There was a low global RR of 8%. DOR in skin ranged from 2·8 to 6·9 months. Median PFS was 5·1 months. Pruritus relief was more frequent in cutaneous responders (67%) than nonresponders (32%). Serial tumour biopsies revealed an increase in acetylated tubulin, indicating a target effect of histone deacetylase 6. Twenty-one of 26 (81%) patients were withdrawn from the study before or at clinical cut-off; five (19%) continued to receive treatment with quisinostat. The most common drug-related adverse events were nausea, diarrhoea, asthenia, hypertension, thrombocytopenia and vomiting. Grade 3 drug-related adverse events included hypertension, lethargy, pruritus, chills, hyperkalaemia and pyrexia. CONCLUSIONS Quisinostat 12 mg three times weekly is active in the treatment of patients with relapsed or refractory CTCL, with an acceptable safety profile. Combination therapy with other drugs active in CTCL may be appropriate.
Collapse
Affiliation(s)
- F Child
- St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K
| | - P L Ortiz-Romero
- Department of Dermatology, 12 de Octubre Hospital, Institute i+12, Medical School, Complutense University, Madrid, Spain
| | - R Alvarez
- Portuguese Institute of Oncology, Lisbon, Portugal
| | - M Bagot
- Department of Dermatology, Saint-Louis Hospital, Paris 7 University, Paris, France
| | - R Stadler
- Department of Dermatology, Johannes Wesling Medical Center, Minden, Germany
| | - M Weichenthal
- Department of Dermatology, University Hospital of Schleswig-Holstein, Kiel, Germany
| | - R Alves
- Department of Dermatology, Hospital de Santo António - Centro Hospitalar do Porto, Porto, Portugal
| | - P Quaglino
- Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy
| | - M Beylot-Barry
- Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France
| | - R Cowan
- Manchester Academic Health Science Centre, Christie Hospital, Manchester, U.K
| | - L J Geskin
- School of Medicine, Department of Dermatology, University of Pittsburgh, Pittsburgh, PA, U.S.A
| | - A Pérez-Ferriols
- Department of Dermatology, University General Hospital, Valencia, Spain
| | - P Hellemans
- Janssen Research & Development, Beerse, Belgium
| | - Y Elsayed
- Janssen Research & Development, Titusville, NJ, U.S.A
| | - C Phelps
- Janssen Research & Development, Titusville, NJ, U.S.A
| | - A Forslund
- Janssen Research & Development, Spring House, PA, U.S.A
| | - M Kamida
- Janssen Pharmaceutical K.K., Tokyo, Japan
| | - P L Zinzani
- Institute of Hematology 'Seràgnoli', University of Bologna, Bologna, Italy
| |
Collapse
|
38
|
Sanz-Motilva V, Castellanos-González M, Martínez Sánchez P, Ortiz de Frutos J, Ortiz-Romero PL, Rodríguez-Peralto JL, Vanaclocha-Sebastián F. [Eczematous lesions and acquired ichthyosis as a presenting finding of CD30+ anaplastic large cell lymphoma]. Semergen 2015; 42:208-10. [PMID: 25817852 DOI: 10.1016/j.semerg.2015.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2014] [Revised: 02/08/2015] [Accepted: 02/09/2015] [Indexed: 10/23/2022]
Affiliation(s)
- V Sanz-Motilva
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España.
| | | | - P Martínez Sánchez
- Servicio de Hematología, Hospital Universitario 12 de Octubre, Madrid, España
| | - J Ortiz de Frutos
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
| | - P L Ortiz-Romero
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
| | - J L Rodríguez-Peralto
- Servicio de Anatomía Patológica, Hospital Universitario 12 de Octubre, Madrid, España
| | | |
Collapse
|
39
|
Fernández-Guarino M, Ortiz-Romero PL, Fernández-Misa R, Montalbán C. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. Actas Dermosifiliogr 2013; 105:438-45. [PMID: 23540593 DOI: 10.1016/j.ad.2012.10.021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2012] [Revised: 10/24/2012] [Accepted: 10/25/2012] [Indexed: 11/16/2022] Open
Abstract
Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma.
Collapse
Affiliation(s)
- M Fernández-Guarino
- Servicio de Dermatología, Hospital Central de la Cruz Roja, Universidad Alfonso X El Sabio, Madrid, España.
| | - P L Ortiz-Romero
- Facultad de Medicina, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid, España
| | - R Fernández-Misa
- Servicio de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España
| | - C Montalbán
- Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, España
| |
Collapse
|
40
|
Peñate Y, Hernández-Machín B, Pérez-Méndez LI, Santiago F, Rosales B, Servitje O, Estrach T, Fernández-Guarino M, Calzado L, Acebo E, Gallardo F, Salar A, Izu R, Ortiz-Romero PL, Pujol RM, Fernández-de-Misa R. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. Br J Dermatol 2012; 167:174-9. [PMID: 22356294 DOI: 10.1111/j.1365-2133.2012.10902.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
BACKGROUND Intravenous rituximab is a safe and effective option for the treatment of systemic non-Hodgkin B-cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B-cell lymphomas (PCBL) has been described in a small number of patients. OBJECTIVES To evaluate the effectiveness, tolerance and adverse effects of ILR in patients with follicle centre (FCL) and marginal zone (MZL) PCBL. METHODS This was an epidemiological observational multicentre study of patients with PCBL treated with ILR. RESULTS Seventeen patients with MZL and 18 with FCL PCBL were included. The median number of lesions treated was two per patient. The treatment regimen used in 74% of the patients was a course of three injections in a single week at 1-month intervals. The dose per lesion and day of treatment was 10 mg in 71% of the patients. The median cumulative dose of rituximab per lesion was 60 mg (range 13-270) and per patient was 150 mg (range 20-360 mg). Complete response (CR) and partial response were achieved in 71% and 23% of patients, respectively. The median time to CR in patients who received 10 mg of ILR per lesion was 8 weeks. Similar response rates were observed in MZL and FCL. Median disease-free survival was 114·1 weeks. No parameters that significantly predicted CR were identified. Adverse reactions were recorded in 19 patients; the most frequent was localized pain at the injection site. Median follow-up was 21 months. CONCLUSIONS Intralesional rituximab is a well-tolerated and effective treatment for FCL and MZL PCBL. It should be considered a useful alternative in patients with recurrent lesions and in which the sequelae of radiotherapy or surgery would be significant.
Collapse
Affiliation(s)
- Y Peñate
- Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Gran Canaria, Las Palmas de GC, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Calzado-Villarreal L, Polo-Rodríguez I, Ortiz-Romero PL. [Primary cutaneous CD30+ lymphoproliferative disorders]. Actas Dermosifiliogr 2010; 101:119-128. [PMID: 20223154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
CD30+ lymphoproliferative disorders are the most common group of cutaneous T-cell lymphomas after mycosis fungoides and its subtypes. This group includes lymphomatoid papulosis and CD30+ anaplastic large-cell lymphoma; these 2 entities are the extremes of a spectrum with numerous intermediate varieties in which it is not possible to establish a clear diagnosis based on clinical and histopathologic criteria. CD30+ lymphoproliferative disorders must be differentiated from other lymphoproliferative diseases with CD30+ cells in the tumor infiltrates, such as mycosis fungoides or Hodgkin disease, and also from other inflammatory conditions or nonhematological neoplasms that can include this cell type, such as pityriasis lichenoides et varioliformis acuta or certain mesenchymal tumors (CD30+ pseudolymphomas). In contrast to their systemic homologues, which arise in the lymph nodes, CD30+ lymphoproliferative disorders generally have a good prognosis. It is very important to exclude the presence of a lymphoma of systemic origin with extralymphatic spread, as the prognosis and treatment are different.
Collapse
Affiliation(s)
- L Calzado-Villarreal
- Unidad de Dermatología, Hospital Universitario Fundación de Alcorcón, Alcorcón, Madrid, Spain
| | | | | |
Collapse
|
42
|
Ortiz-Romero PL. [Photopheresis]. Actas Dermosifiliogr 2009; 100:443-444. [PMID: 19709547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Affiliation(s)
- P L Ortiz-Romero
- Servicio de Dermatología, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. portiz@
| |
Collapse
|
43
|
Ortiz-Romero PL, Corell-Almuzara A, Lopez-Estebaranz JL, Arranz FR, Ruiz-Contreras J. Lupus like lesions in a patient with X-linked chronic granulomatous disease and recombinant X chromosome. Dermatology 1998; 195:280-3. [PMID: 9407182 DOI: 10.1159/000245963] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Lupus-like lesions in X-linked chronic granulomatous disease (X-CGD) are rare. To our knowledge, only 2 cases have previously been published. We report a 2.5-year-old boy with X-CGD whose clinical findings were consistent with cutaneous lupus erythematosus. Conventional histopathology showed epidermal atrophy, parakeratosis, follicular plugging and areas of hydropic degeneration. The most striking feature was a neutrophilic interstitial infiltrate with leukocytoclasia in the upper dermis. The X chromosome of our patient--studied with 2 endonucleases (PstI and TaqI) and 5 probes (P99.6, pERT 87.8, pERT87.15, XJ1.1 and 754)--was recombinant, but we believe that this is an incidental finding, not related to the disease. Neutrophilic infiltrate and leukocytoclasia could be characteristic histopathologic findings of lupus-like lesions in these patients.
Collapse
Affiliation(s)
- P L Ortiz-Romero
- Service of Dermatology, Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain.
| | | | | | | | | |
Collapse
|
44
|
de Argila D, Ortiz-Romero PL, Ortiz-Frutos J, Rodriguez-Peralto JL, Iglesias L. Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. Clin Exp Dermatol 1996; 21:313-4. [PMID: 8959910 DOI: 10.1111/j.1365-2230.1996.tb00106.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Cutaneous amyloidosis and multiple endocrine neoplasia 2A (MEN 2A) have been previously reported in several families. A genetic linkage of both disorders has recently been described. Notalgia paraesthetica has been suggested to be involved in the aetiology of amyloidosis in such patients. We report such an association in a 48-year-old woman with several relatives suffering from MEN 2A. Treatment with topical capsaicin, which has been shown to be effective in notalgia paraesthetica, was not useful in our patient.
Collapse
Affiliation(s)
- D de Argila
- Department of Dermatology, Hospital Universitario Doce de Octubre, Madrid, Spain
| | | | | | | | | |
Collapse
|
45
|
Ortiz-Romero PL, Ballestin-Carcavilla C, Lopez-Estebaranz JL, Iglesias-Diez L. Clinicopathologic and immunohistochemical studies on lichen amyloidosis and macular amyloidosis. Arch Dermatol 1994; 130:1559-60. [PMID: 7527208 DOI: 10.1001/archderm.130.12.1559] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|